Table 1.
Data from | Wild type or resistance# | Synergistic combination | Reference |
---|---|---|---|
In vitro Animal | Wild type and Resistance | Beauvericin + Clotrimazole, or Fluconazole, or Itraconazole, or Ketoconazole, or Miconazole | Unpublished |
In vitro | Wild type and Resistance | Rapamycin + peptides | Unpublished |
In vitro | Wild type and Resistance | Ketoconazole + Avilamycin | Unpublished |
In vitro | Wild type and Resistance | Ketoconazole + Spinosad | Unpublished |
In vitro | Wild type and Resistance | Nitroimidazoles + Amphotericin B | 83 |
In vitro | Wild type and Resistance | Histatin 5 and its analogs Amphotericin B | 84 |
In vitro | Wild type and Resistance | Tetrandrine + Ketoconazole | 85 |
In vitro | Wild type and Resistance | Fluconazole + Thymol, or Carvacrol | 86 |
In vitro | Wild type and Resistance | Geldanamycin + Fluconazole | 87 |
In vitro | Wild type and Resistance | Pure polyphenol curcumin I + Fluconazole, or Miconazole, or Ketoconazole, or Itraconazole, or Voriconazole, or Nystatin or Amphotericin B | 88 |
In vitro | Wild type and Resistance | Berberine + Fluconazole | 89-91 |
In vitro | Wild type and Resistance | Fluconazole + alverine citrate, or Caspofungin, Latrunculin-A, or Wortmannin, or Fenpropimorph | 92 |
In vitro | Wild type and Resistance | Tunicamycin + FK506, or Cyclosporine-A | 92 |
In vitro | Wild type and Resistance | Wortmannin + Tunicamycin, or FK506 | 92 |
In vitro | Wild type and Resistance | Posaconazole + Caspofungin, or FK506 | 93 |
In vitro | Wild type and resistance | Amphotericin B + Terbinafine | 94 |
In vitro | Wild type and Resistance | Flucytosine + Econazole, or Miconazole | 95 |
In vitro | Wild type and Resistance | Fluvastatin + Fluconazole, or Itraconazole | 96 |
In vitro | Wild type and Resistance | FK506 + Fluconazole, or Voriconazole, or Itraconazole | 97 |
In vitro | Wild type and Resistance | Retigeric acid B + Fluconazole, or Ketoconazole, or Itraconazole | 98 |
In vitro | Wild type and Resistance | Lactoferrin + Fluconazole, or Itraconazole | 99 |
In vitro | Wild type and Resistance | Farnesol + Fluconazole, or Ketoconazole, or Miconazole, or Amphotericin B | 100 |
In vitro | Wild type and Resistance | Amiodarone + Fluconazole, or Voriconazole, or Itraconazole | 101 |
In vitro | Resistance | Eugenol + Amphotericin B, or Fluconazole | 102 |
In vitro | Resistance | Honokiol + Fluconazole | 103 |
In vitro | Resistance | Glabridin + Fluconazole | 104 |
In vitro | Resistance | Tioconazole + Butylated hydroxyanisole | 105 |
In vitro | Resistance | Baicalein + Amphotericin B | 106 |
In vitro | Resistance | Curcumin+ R6G, or Ketoconazole, or Itraconazole, or Miconazole | 107 |
In vitro | Resistance | Anidulafungin + Posaconazole, or Amphotericin B | 108 |
In vitro | Resistance | Caspofungin + Posaconazole, or Micafungin | 108 |
In vitro | Resistance | Minocycline + Fluconazole | 109 |
In vitro | Resistance | Baicalein + Fluconazole | 110 |
In vitro | Resistance | Ofloxacin + Fluconazole | 111 |
In vitro | Biofilm and Planktonic cells | Fluconazole + FK506, or Cyclosporine A | 112 |
In vitro | Biofilm and Planktonic cells | Berberine + Miconazole | 113 |
In vitro | Biofilm and Planktonic cells | Aspirin + Amphotericin B | 114 |
In vitro | Biofilm | Tyrocidines + Amphotericin B, or Caspofungin | 115 |
In vitro | Biofilm | Amphotericin B + Drospirenone, or Perhexiline, or Toremifene | 116 |
In vitro | Biofilm | Caspofungin + Drospirenone, or Perhexiline, or Toremifene | 116 |
In vitro | Biofilm | Amphotericin B + N-acetylcysteine, or EDTA, or Ethanol, or Talactoferrin | 117 |
In vitro | Biofilm | Fluconazole + N-acetylcysteine, or EDTA, or Ethanol, or Talactoferrin | 117 |
In vitro | Biofilm | Terpenes + Fluconazole | 118 |
In vitro | Biofilm | Doxycycline + Fluconazole | 119 |
In vitro | Biofilm | Silver nanoparticles + nystatin, or chlorhexidine digluconate | 120 |
In vitro | Biofilm | Doxycycline + Fluconazole | 121 |
In vitro | Biofilm | Shearinines D (3) and E (4) + Amphotericin B | 122 |
In vitro | Biofilm | Verapamil + Fluconazole, or Tunicamycin | 123 |
In vitro | Biofilm | Cyclosporine A + Fluconazole, or Voriconazole, or Amphotericin B, or Caspofungin | 124 |
In vitro | Biofilm | Amphotericin B + Rifampicin, or Clarithromycin | 125 |
Animal | Wild type and resistance | Posaconazole + Caspofungin, or FK506 | 126 |
Animal | Resistance | Amphotericin B + Caspofungin | 127 |
Animal | Resistance | Tetrandrine + Ketoconazole | 128 |
Animal | Wild type | Berberine + Amphotericin B | 129 |
Animal | Wild type | Cilofungin + Amphotericin B | 130 |
Animal | Wild type | Antimicrobial peptides + Caspofungin | 131 |
Animal | Wild type | Nikkomycin Z + R 3783 | 132 |
Animal | Wild type | Amphotericin B + Ketoconazole, or 5-Fluorocytosine | 133 |
Animal | Wild type | 5-Fluorocytosine + Fluconazole, or Itraconazole | 133 |
Animal | Biofilm | Fluconazole + FK506, or Cyclosporine A | 112 |
Clinic trials | Clinical | Amphotericin B + 5-Fluorocytosine | 134-137 |
Clinic trials | Clinical | 5-Fluorocytosine + Azoles | 138 |
Clinic trials | Clinical | Amphotericin B + Azoles | 139 |
Clinic trials | Clinical | Terbinafine + Itraconazole or Fluconazole | 140 |
Clinic trials | Clinical | Mycograb + lipid-associated amphotericin B | 141 |
Because strains, culture conditions, susceptibility testing methods and models used to define synergy in these studies were different, results from different literatures may be contrary to each other, only synergy reports were selected in this table.
Strains were labeled as wild type if they were not claimed as resistance explicitly in the reference. For clinical trials, the infection sources are not distinguished, all labeled as clinical.